DLA Piper advises Akoya Biosciences in its business combination with Quanterix

DLA Piper advised Akoya Biosciences (Akoya), The Spatial Biology Company®, a leading biotechnology company, in entering into a definitive agreement to be acquired by Quanterix Corporation (Quanterix), a company fueling scientific discovery through ultra-sensitive biomarker detection.

The all-stock transaction will create the first integrated solution for ultra-sensitive detection of blood and tissue-based protein biomarkers. The complementary offerings of the companies will expand technology offerings across high growth markets in neurology, oncology and immunology; expand lab services and clinical diagnostic market opportunities; consolidate cash balances; and increase commercial reach and maximize cross-selling opportunities.

The DLA Piper team that advised Akoya was co-led by partners David Clark and Patrick O’Malley (both in San Diego) and included associates Carina Meleca (New York) and Nick Bolduc (Raleigh).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 15 consecutive years, according to Mergermarket, and ranked as a top five most active VC legal advisor in the US and number one in VC, PE and M&A in combined global deal volume according to PitchBook.